Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Mega-randomized clinical trials for blockbuster drugs--reply.

Ioannidis JP.

JAMA. 2013 Apr 24;309(16):1683. doi: 10.1001/jama.2013.2742. No abstract available.

PMID:
23613069
2.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Suman VJ, Dueck A, Sargent DJ.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Review. No abstract available.

PMID:
18568764
3.

Design of randomized controlled trials.

Stanley K.

Circulation. 2007 Mar 6;115(9):1164-9. Review. No abstract available.

4.

Design of cancer screening trials/randomized trials for evaluation of cancer screening.

Miller AB.

World J Surg. 2006 Jul;30(7):1152-62. Review. No abstract available.

PMID:
16794902
5.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

6.

Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.

Rheims S, Perucca E, Cucherat M, Ryvlin P.

Epilepsia. 2011 Feb;52(2):219-33. doi: 10.1111/j.1528-1167.2010.02915.x. Epub 2011 Jan 26. Review.

7.

[Surrogate end point fallacies -- the urge for randomized trials with clinical endpoints].

Mühlhauser I, Meyer G.

Psychother Psychosom Med Psychol. 2006 May;56(5):193-201. Epub 2006 Mar 3. Review. German.

PMID:
16586306
8.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.

Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F; American Heart Association.

Circulation. 2004 Jun 1;109(21):e302-4. Review. No abstract available.

9.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.

Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F; American Heart Association.

Circulation. 2004 Jun 1;109(21):e305-7. Review. No abstract available.

10.

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.

D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO).

Gastroenterology. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Review.

PMID:
23000597
11.
12.

Mega-trials: methodological issues and clinical implications.

Charlton BG.

J R Coll Physicians Lond. 1995 Mar-Apr;29(2):96-100. Review.

PMID:
7595900
13.

Randomized phase II trials: a long-term investment with promising returns.

Sharma MR, Stadler WM, Ratain MJ.

J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27. Review.

14.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
15.

End points and clinical trial design in pulmonary arterial hypertension.

McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. doi: 10.1016/j.jacc.2009.04.007. Review.

16.

Forty years of antidepressant drug trials.

Barbui C, Hotopf M.

Acta Psychiatr Scand. 2001 Aug;104(2):92-5. Review.

PMID:
11473501
17.

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.

Sridhara R, Mandrekar SJ, Dodd LE.

Clin Cancer Res. 2013 May 15;19(10):2613-20. doi: 10.1158/1078-0432.CCR-12-2938. Review.

18.

Quality of life assessment in surgical oncology trials.

Avery K, Blazeby JM.

World J Surg. 2006 Jul;30(7):1163-72. Review.

PMID:
16794901
19.

Factors to consider in determining the feasibility of randomized clinical trials.

Dainty K, Karlsson J; ISAKOS Scientific Committee.

Arthroscopy. 2003 Oct;19(8):882-4. Review.

PMID:
14551554
20.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4.

Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Review.

PMID:
20156955
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk